CELLECTAR BIOSCIENCES, INC.
100 Campus Drive
Florham Park, New Jersey 07932
June 1, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Abby Adams
| Re: | Cellectar Biosciences, Inc. |
Registration Statement on Form S-1
File No. 333-238132
Acceleration Request
Requested Date:
Tuesday, June 2, 2020
Requested Time:
4:15 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-1 (Registration No. 333-238132), as amended, be accelerated so that the Registration Statement will become effective at 4:15 p.m. on June 2, 2020, or as soon as practicable thereafter, or at such later time as the Company or its legal counsel may orally request via telephone call to the staff. The Company hereby authorizes Gregory J. Lynch of Michael Best & Friedrich LLP to make such request on its behalf.
The cooperation of the staff in meeting our request is very much appreciated. If you have any questions or comments, please contact Gregory J. Lynch of Michael Best & Friedrich LLP at (608) 283-2240 or gjlynch@michaelbest.com or Joshua B. Erekson of Michael Best & Friedrich LLP at (801) 833-0505 or jberekson@michaelbest.com. Thank you for your assistance with these matters.
Very truly yours, | |||
| CELLECTAR BIOSCIENCES, INC. | |||
| By: | /s/ Dov Elefant | ||
| Dov Elefant, Vice President and Chief Financial Officer | |||
| cc: | James V. Caruso Gregory J. Lynch |
